Literature DB >> 11411800

Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse.

R Mancinelli1, A Fabrizi, S Del Monaco, G B Azzena, R Vargiu, G C Colombo, G L Gessa.   

Abstract

The effects of the cannabinoid receptor agonist Win 55,212-2 and of the competitive cannabinoid receptor antagonist SR 141716A on the electrically-evoked peristalsis of isolated distal colon of mouse were studied. Intraluminal pressure, longitudinal displacement, ejected fluid volume and changes in morphology of external intestinal wall were simultaneously recorded in the pre-drug period and in presence of Win 55,212-2 alone or in combination with SR 141716A. In the pre-drug period (control), peristaltic activity was characterised by regular, monophasic waves and the intraluminal content propelled towards anterograde (oro-aboral) direction with a propulsion velocity of 1.25 +/- 0.1 mm x s(-1). Pressure and shortening waves showed a peak amplitude of 2.44 +/- 0.32 kPa and 1.8 +/- 0.72 mm, respectively. The mean amount of fluid volume ejected during each contraction was 80 +/- 12.6 microl. The addition of Win 55,212-2 [10(-7)-10(-4) M] to the organ bath determined a dose-related attenuation of peristaltic activity consequent to the decrease of circular and longitudinal muscle strength. The decrease of contractile activity was followed by dose-dependent decrease of the amount of fluid ejected during peristalsis. The effects of Win 55,212-2 [10(-7)-10(-5) M] were prevented by SR 141716A, indicating the presence of cannabinoid CB1 receptors in the mouse distal colon. SR 141716A alone enhanced both tonic and phasic motor activities in the colonic longitudinal smooth muscle, suggesting that CB1 receptor antagonists could act either through antagonising the effect of endogenous CB1 receptor agonist or by an agonist effect on these receptors. The present results further support the hypothesis that cannabinoids perform a neuromodulatory role in various tracts of gastrointestinal system and first demonstrate their action also in the distal colon of rodents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11411800     DOI: 10.1016/s0024-3205(01)01110-9

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  11 in total

Review 1.  Treating irritable bowel syndrome: overview, perspective and future therapies.

Authors:  Michael Camilleri
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

Review 2.  Involvement of cannabinoid receptors in gut motility and visceral perception.

Authors:  Pamela J Hornby; Stephen M Prouty
Journal:  Br J Pharmacol       Date:  2004-04       Impact factor: 8.739

3.  Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice.

Authors:  M A Storr; M Bashashati; C Hirota; V K Vemuri; C M Keenan; M Duncan; B Lutz; K Mackie; A Makriyannis; W K Macnaughton; K A Sharkey
Journal:  Neurogastroenterol Motil       Date:  2010-02-24       Impact factor: 3.598

Review 4.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 5.  Endocannabinoids and the gastrointestinal tract: what are the key questions?

Authors:  G J Sanger
Journal:  Br J Pharmacol       Date:  2007-09-03       Impact factor: 8.739

6.  Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents.

Authors:  Tiziano Croci; Marco Landi; Anne-Marie Galzin; Pietro Marini
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

7.  Modulation of motor and sensory pathways of the peristaltic reflex by cannabinoids.

Authors:  John R Grider; Sunila Mahavadi; Yan Li; Li-Ya Qiao; John F Kuemmerle; Karnam S Murthy; Billy R Martin
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-09       Impact factor: 4.052

Review 8.  Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).

Authors:  Hester van Diepen; Eberhard Schlicker; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-25       Impact factor: 3.000

9.  Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon.

Authors:  Nicholas M Hinds; Katja Ullrich; Scott D Smid
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

10.  Rimonabant, gastrointestinal motility and obesity.

Authors:  Yan Sun; Jiande Dz Chen
Journal:  Curr Neuropharmacol       Date:  2012-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.